Compare · NTHI vs NVO
NTHI vs NVO
Side-by-side comparison of NeOnc Technologies Holdings Inc. (NTHI) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTHI and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $211.73B, about 1673.0x NTHI ($126.6M).
- Over the past year, NTHI is up 35.9% and NVO is down 33.0% - NTHI leads by 68.9 points.
- NTHI has been more active in the news (19 items in the past 4 weeks vs 3 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 3 for NTHI).
- Company
- NeOnc Technologies Holdings Inc.
- Novo Nordisk A/S
- Price
- $4.92-4.84%
- $47.40+3.29%
- Market cap
- $126.6M
- $211.73B
- 1M return
- -9.06%
- +6.83%
- 1Y return
- +35.91%
- -32.98%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 19
- 3
- Recent ratings
- 3
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NTHI
- SEC Form DEFA14A filed by NeOnc Technologies Holdings Inc.
- SEC Form DEF 14A filed by NeOnc Technologies Holdings Inc.
- NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 424B5 filed by NeOnc Technologies Holdings Inc.
- These Emerging Companies Are Racing Toward Major Catalysts
- NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone
- International Regulatory Pathways Have Supported Drug Development Across Biotech and Pharma
- NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Biotech's New Frontier: Companies Breaking Through Medicine's Toughest Barriers
- NeOnc's Global Expansion Accelerates After Abu Dhabi IND Approval for NEO212
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S